Related Experiment Video

Updated: Oct 20, 2025

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.1K

Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer

Erinna F Lee1,2,3, W Douglas Fairlie1,2,3

  • 1La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria 3086, Australia.

Biochemical Society Transactions
|September 13, 2021
PubMed

Insights

Scientists discovered BH3-mimetics, drugs targeting anti-apoptotic proteins like BCL-2, revolutionizing cancer treatment. This success story highlights basic science translating into effective cancer therapies.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Oncology

Background:

  • The BCL-2 protein, implicated in cancer, was identified over 30 years ago.
  • Understanding the mechanism of action of BCL-2 and related proteins was crucial.

Purpose of the Study:

  • To chart the discovery and evolution of BH3-mimetics.
  • To highlight their application in cancer treatment.

Main Methods:

  • Review of scientific literature on BCL-2 family proteins.
  • Analysis of the development of small molecule inhibitors.
  • Examination of clinical applications of BH3-mimetics.

Main Results:

  • Identification of a new class of small molecule compounds targeting BCL-2 family proteins.
  • Development of BH3-mimetics as the first drugs to inhibit protein-protein interactions.
  • Successful application of these drugs in cancer therapy.

Conclusions:

  • The discovery of BH3-mimetics represents a major translational success from basic science.
  • These drugs specifically target anti-apoptotic proteins, offering a novel cancer treatment strategy.
  • The history of BH3-mimetics showcases the power of understanding molecular mechanisms for therapeutic development.
Keywords:
BCL-2BCL-XLBH3-mimeticsMCL-1apoptosis

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.8K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K